Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

Recs

1
Player Avatar supez2004 (35.23) Submitted: 3/3/2008 1:13:01 AM : Underperform Start Price: $5.75 KERX Score: -77.34

Phase 3 for sulodexide unlikely to impress ...

Member Avatar AARCUDA22 (48.37) Submitted: 10/31/2009 11:22:01 AM
Recs: 0

PHASE 3 COMING BEFORE THE END OF YEAR.GREAT STOCK TO LOAD UP AND HOLD!!!!!!!!!!!

Featured Broker Partners


Advertisement